TAILS N-Terminomics and Proteomics Show Protein Degradation Dominates over Proteolytic Processing by Cathepsins in Pancreatic Tumors.

Deregulated cathepsin proteolysis occurs across numerous cancers, but in vivo substrates mediating tumorigenesis remain ill-defined. Applying 8-plex iTRAQ terminal amine isotopic labeling of substrates (TAILS), a systems-level N-terminome degradomics approach, we identified cathepsin B, H, L, S, and Z in vivo substrates and cleavage sites with the use of six different cathepsin knockout genotypes in the Rip1-Tag2 mouse model of pancreatic neuroendocrine tumorigenesis. Among 1,935 proteins and 1,114 N termini identified by TAILS, stable proteolytic products were identified in wild-type tumors compared with one or more different cathepsin knockouts (17%-44% of 139 cleavages). This suggests a lack of compensation at the substrate level by other cathepsins. The majority of neo-N termini (56%-83%) for all cathepsins was consistent with protein degradation. We validated substrates, including the glycolytic enzyme pyruvate kinase M2 associated with the Warburg effect, the ER chaperone GRP78, and the oncoprotein prothymosin-alpha. Thus, the identification of cathepsin substrates in tumorigenesis improves the understanding of cathepsin functions in normal physiology and cancer.

[1]  C. Yeo,et al.  Neuroendocrine tumors of the pancreas , 2012, Current opinion in oncology.

[2]  J. Whisstock,et al.  AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP , 2006, Nature.

[3]  C. Overall,et al.  Multiplex N-terminome Analysis of MMP-2 and MMP-9 Substrate Degradomes by iTRAQ-TAILS Quantitative Proteomics* , 2010, Molecular & Cellular Proteomics.

[4]  Amy S. Lee,et al.  The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies , 2013, Oncogene.

[5]  C. Overall,et al.  Proteolytic Post-translational Modification of Proteins: Proteomic Tools and Methodology* , 2013, Molecular & Cellular Proteomics.

[6]  M. Jäättelä,et al.  Cancer-associated lysosomal changes: friends or foes? , 2013, Oncogene.

[7]  Christopher M. Overall,et al.  A Statistics-based Platform for Quantitative N-terminome Analysis and Identification of Protease Cleavage Products , 2010, Molecular & Cellular Proteomics.

[8]  Christopher M Overall,et al.  Identifying and quantifying proteolytic events and the natural N terminome by terminal amine isotopic labeling of substrates , 2011, Nature Protocols.

[9]  D. Hanahan,et al.  Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.

[10]  O. Schilling,et al.  Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. , 2011, Journal of proteome research.

[11]  Bonnie F. Sloane,et al.  Cathepsin C is a tissue-specific regulator of squamous carcinogenesis , 2013, Genes & development.

[12]  R. Aebersold,et al.  Quantitative proteomics investigation of pancreatic intraepithelial neoplasia , 2009, Electrophoresis.

[13]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[14]  S. L. Berger,et al.  Nuclear targeting of prothymosin alpha. , 1991, The Journal of biological chemistry.

[15]  Christopher M. Overall,et al.  Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.

[16]  M. Frangou-Lazaridis,et al.  Surfing on prothymosin alpha proliferation and anti-apoptotic properties. , 2006, Neoplasma.

[17]  J. Joyce,et al.  Pericellular proteolysis in cancer , 2014, Genes & development.

[18]  R. Sousa,et al.  Structural basis of interdomain communication in the Hsc70 chaperone. , 2005, Molecular cell.

[19]  K. Gevaert,et al.  Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells* , 2015, Molecular & Cellular Proteomics.

[20]  C. Overall,et al.  Cysteine Cathepsins Activate ELR Chemokines and Inactivate Non-ELR Chemokines* , 2015, The Journal of Biological Chemistry.

[21]  L. Ellerby,et al.  Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78 , 2002, FEBS letters.

[22]  Christopher M. Overall,et al.  CLIPPER: an add-on to the Trans-Proteomic Pipeline for the automated analysis of TAILS N-terminomics data , 2012, Biological chemistry.

[23]  J. Joyce,et al.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response , 2015, Nature Reviews Cancer.

[24]  A. Mesecar,et al.  Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. , 2005, Biochemistry.

[25]  R. Kalluri,et al.  Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.

[26]  S. Maurer-Stroh,et al.  Analysis of Protein Processing by N-terminal Proteomics Reveals Novel Species-specific Substrate Determinants of Granzyme B Orthologs *S , 2009, Molecular & Cellular Proteomics.

[27]  J. Joyce,et al.  Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer , 2016, Genes & development.

[28]  Sharon Yang,et al.  Proteome TopFIND 3.0 with TopFINDer and PathFINDer: database and analysis tools for the association of protein termini to pre- and post-translational events , 2014, Nucleic Acids Res..

[29]  Christian M. Metallo,et al.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.

[30]  C. Peters,et al.  Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer , 2010, Biological chemistry.

[31]  V. Agol,et al.  Prothymosin α fragmentation in apoptosis , 2000 .

[32]  L. Coussens,et al.  Delineating protease functions during cancer development. , 2009, Methods in molecular biology.

[33]  L. Mazzucchelli,et al.  Function of Liver Activation-Regulated Chemokine/CC Chemokine Ligand 20 Is Differently Affected by Cathepsin B and Cathepsin D Processing1 , 2006, The Journal of Immunology.

[34]  Laura H. Tang,et al.  Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix , 2014, Genes & development.

[35]  Weiwei Yang,et al.  Regulation and function of pyruvate kinase M2 in cancer. , 2013, Cancer letters.

[36]  L. Foster,et al.  Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products , 2010, Nature Biotechnology.

[37]  W. Hahn,et al.  Analysis of tumor- and stroma-supplied proteolytic networks reveals a brain metastasis-promoting role for cathepsin S , 2014, Nature Cell Biology.

[38]  F. Filipp Cancer metabolism meets systems biology: Pyruvate kinase isoform PKM2 is a metabolic master regulator , 2013, Journal of carcinogenesis.

[39]  U. Eckhard,et al.  The Human Dental Pulp Proteome and N-Terminome: Levering the Unexplored Potential of Semitryptic Peptides Enriched by TAILS to Identify Missing Proteins in the Human Proteome Project in Underexplored Tissues. , 2015, Journal of proteome research.

[40]  L. Coussens,et al.  Protective role of cathepsin L in mouse skin carcinogenesis , 2012, Molecular carcinogenesis.

[41]  W. Delano The case for open-source software in drug discovery. , 2005, Drug discovery today.

[42]  D. Wolters,et al.  The Apaf-1-binding protein Aven is cleaved by Cathepsin D to unleash its anti-apoptotic potential , 2012, Cell Death and Differentiation.

[43]  Bonnie F. Sloane,et al.  Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. , 2013, Neoplasia.

[44]  M. Bogyo,et al.  A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. , 2004, Molecular cell.

[45]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[46]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.

[47]  B. Fingleton,et al.  Systems-Level Analysis of Proteolytic Events in Increased Vascular Permeability and Complement Activation in Skin Inflammation , 2013, Science Signaling.

[48]  Marco Biasini,et al.  SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information , 2014, Nucleic Acids Res..

[49]  O. Vasiljeva,et al.  Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice , 2008, Oncogene.

[50]  O. Vasiljeva,et al.  Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice , 2010, Proceedings of the National Academy of Sciences.

[51]  J. Kofron,et al.  Distinctive Roles of PHAP Proteins and Prothymosin-α in a Death Regulatory Pathway , 2003, Science.

[52]  Olga Vasiljeva,et al.  Cysteine cathepsins: From structure, function and regulation to new frontiers , 2011, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics.

[53]  C. Peters,et al.  Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis , 2010, Oncogene.